Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donal McLornan

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Best Practice & Research. Clinical Haematology|November 4, 2022
PrefaceDonal McLornan
Journal of Cellular and Molecular Medicine|December 31, 2013
Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?Donal McLornan, Claire Harrison
Hematology (Amsterdam, Netherlands)|March 12, 2014
MyelofibrosisClaire Harrison, Donal McLornan
Expert Review of Hematology|September 8, 2015
The use of JAK inhibitors for low-risk myelofibrosisSamah Alimam, Donal McLornan, Claire Harrison
Expert Opinion on Drug Safety|June 5, 2014
Safety evaluation of ruxolitinib for treating myelofibrosisSofia Galli, Donal McLornan, Claire Harrison
Expert Review of Hematology|June 3, 2017
Managing side effects of JAK inhibitors for myelofibrosis in clinical practiceIram Saeed, Donal McLornan, Claire N Harrison
The Ulster Medical Journal|June 8, 2006
JAK2 V617F: a single mutation in the myeloproliferative group of disordersDonal McLornan, Melanie Percy, Mary Frances McMullin
British Journal of Haematology|February 23, 2024
The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMTAngela Hwang, Patrick Hayden, Charlotte Pawlyn, et al.
British Journal of Haematology|November 20, 2020
Uniparental disomy (UPD) of a novel bisphosphoglycerate mutase (BPGM) mutation leading to erythrocytosisIoanna Lazana, Azim Mohamedali, Frances Smith, et al.
Hemasphere|November 15, 2019
Ruxolitinib for the Treatment of Essential ThrombocythemiaArief Gunawan, Patrick Harrington, Natalia Garcia-Curto, et al.
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Best Practice & Research. Clinical Haematology|November 4, 2022
PrefaceDonal McLornan
Journal of Cellular and Molecular Medicine|December 31, 2013
Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?Donal McLornan, Claire Harrison
Hematology (Amsterdam, Netherlands)|March 12, 2014
MyelofibrosisClaire Harrison, Donal McLornan
Expert Review of Hematology|September 8, 2015
The use of JAK inhibitors for low-risk myelofibrosisSamah Alimam, Donal McLornan, Claire Harrison
Expert Opinion on Drug Safety|June 5, 2014
Safety evaluation of ruxolitinib for treating myelofibrosisSofia Galli, Donal McLornan, Claire Harrison
Expert Review of Hematology|June 3, 2017
Managing side effects of JAK inhibitors for myelofibrosis in clinical practiceIram Saeed, Donal McLornan, Claire N Harrison
The Ulster Medical Journal|June 8, 2006
JAK2 V617F: a single mutation in the myeloproliferative group of disordersDonal McLornan, Melanie Percy, Mary Frances McMullin
British Journal of Haematology|February 23, 2024
The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMTAngela Hwang, Patrick Hayden, Charlotte Pawlyn, et al.
British Journal of Haematology|November 20, 2020
Uniparental disomy (UPD) of a novel bisphosphoglycerate mutase (BPGM) mutation leading to erythrocytosisIoanna Lazana, Azim Mohamedali, Frances Smith, et al.
Hemasphere|November 15, 2019
Ruxolitinib for the Treatment of Essential ThrombocythemiaArief Gunawan, Patrick Harrington, Natalia Garcia-Curto, et al.
Pageof 7